The audit of the interim report has been carried out due to the contemplated rights issue in the Company and the prospectus that is being prepared in connection thereto. The audited interim report is available in Swedish on the Company's website:https://www.mobergpharma.se/investerare/prospekt
For additional information, please contact:
Anna Ljung, CEO, Phone: + 46 70 766 60 30, e-post: email@example.com
Mark Beveridge, VP Finance, Phone: + 46 76 805 82 88, e-post: firstname.lastname@example.org
About Moberg Pharma, www.mobergpharma.com
Moberg Pharma AB (publ) is a Swedish pharmaceutical company focused on commercializing proprietary innovations based on drug delivery of proven compounds. The Company's main asset, MOB-015, is a novel topical treatment for onychomycosis, with recently completed phase 3 trials in more than 800 patients. The pipeline also includes the late-stage asset BUPI for pain relief in oral mucositis, intended to be spun off in the separate company OncoZenge. Clinical data generated for both assets indicate they have the potential to become market leaders in their respective niches. Moberg Pharma is headquartered in Stockholm and the Company's shares are listed on the Small Cap list of Nasdaq Stockholm (OMX: MOB).
Moberg Pharma AB published this content on 27 November 2020 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 27 November 2020 14:32:07 UTC